arrow
W

Weina Sun

Icahn School of Medicine at Mount Sinai
H指数:27
被引数:2,194

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunodominance hierarchy of influenza A haemagglutinin antigenic sites: an observational cohort study across distinct exposure histories

甲型流感血凝素抗原位点的免疫优势层级:一项跨越不同暴露史的观察性队列研究

2026-08-060
OA
Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults

先前接种过疫苗的成人鼻腔内接种NDV-HXP-S的I期临床试验

Vaccine
IF3.5
2026-06-010
PRE
Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters

同源和异源NDV和MVA SARS-CoV-2疫苗在小鼠和沙鼠中的免疫原性和效力

2025-11-210
OAAI
Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination

接种KP.2单价mRNA疫苗后,对SARS-CoV-2变异株LP.8.1、LF.7.1、NB.1.8.1、XFG和BA.3.2的抗体应答

MBIO
IF4.7
2025-11-012
PRE
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil

重组新城病病毒灭活疫苗表达SARS-CoV-2刺突蛋白的安全性及免疫原性:巴西随机疫苗对照的I期ADAPTCOV试验结果

VACCINE
IF3.5
2025-04-010
PRE
A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
2025-01-030
PRE
Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach

基于镶嵌血凝素方法的通用乙型流感灭活疫苗的临床前评估

2024-11-170
OAAI
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination

SARS-CoV-2 mRNA疫苗诱导的人非中和交叉反应性刺突抗体的保护作用和分子机制

2024-11-010
OAAI
Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity
2024-09-160
OAAI
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals
2024-05-301
OAAI
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

墨西哥基于NDV的新型冠状病毒肺炎疫苗I期试验的临时安全性和免疫原性结果

2023-05-1023
OAAI